Hematologic impact of antibiotic administration on patients taking clozapine

Innovations in Clinical Neuroscience

Volumn 9, Issue 11-12, 2012, Pages 18-30

  Shuman, Michael ^a   lee Demler, Tammie ^b   Trigoboff, Eileen ^b   Opler, Lewis A ^c  

^a Buffalo Psychiatric Center   (United States)

^b University of New York   (United States)

^c Department of Medicine   (United States)

Author keywords

Antibiotic; Clozapine; Hematology; Psychiatry; Schizophrenia; Side effect

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLOZAPINE; MOXIFLOXACIN; PENICILLIN DERIVATIVE;

AGRANULOCYTOSIS; ANTIBIOTIC THERAPY; ARTICLE; BLOOD DYSCRASIA; CLINICAL ARTICLE; CORRELATION COEFFICIENT; DRUG MECHANISM; DRUG POTENTIATION; DRUG USE; DRUG WITHDRAWAL; HEMATOLOGICAL PARAMETERS; HUMAN; INFECTION CONTROL; LEUKOCYTE COUNT; MONOTHERAPY; NEUTROPENIA; NEUTROPHIL COUNT; PILOT STUDY; PSYCHIATRIC TREATMENT; RETROSPECTIVE STUDY; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84874341381     PISSN: 21588333     EISSN: 21588341     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Demler TL, Trigoboff E. Are clozapine blood dyscrasias associated with concomitant medications? Innov Clin Neurosci. 2011;8:35-41.
2. Raja M, Azzoni A, Maisto G. Late onset neutropenia associated with clozapine. J Clin Psychopharmacol. 2011;31:780-781.
3. Clozaril [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2011.
4. Andersohn F, Konzen C, Garbe E. Systemic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007;146:657-665.
5. Paul W. Fundamental Immunology. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
6. Lim EM, Cembrowski G, Cembrowski M, Clarke G. Race-specific WBC and neutrophil count reference intervals. Int J Lab Hematol. 2010;32(6 Pt 2):590-597.
7. Schwartzberg LS. Neutropenia: etiology and pathogenesis. Clinical Cornerstone 2006;8(Suppl 5):S5-S11.
8. Dancey JT, Deubelbeiss KA, Harker LA, Finch CA. Neutrophil kinetics in man. J Clin Invest. 1976;58(3):705-715.
9. Takumi K, Garssen J, de Jonge R, et al. Release kinetics and cell trafficking in relation to bacterial growth explain the time course of blood neutrophils and monocytes during primary Salmonella infection. Int Immunol. 2005;17(1):85-93.
10. Parham P. The Immune System, Third Edition. New York, NY: Garland Science; 2009:506.
11. Marsh JC, Boggs D, Cartwright E, Wintrobe M. Neutrophil kinetics in acute infection. J Clin Invest. 1967;46:1943-1953.
12. Price TH, Lee M, Dale D, Finch C. Neutrophil kinetics in chronic neutropenia. Blood.1979;54:581-594.
13. Altenburg J, de Graaf C, van der Werf T, Boersma W. Immunomodulatory effects of macrolide antibiotics. part 1: biological mechanisms. Respiration. 2011;81:67-74.
14. Koch CC, Esteban D, Chin A, et al. Apoptosis, oxidative metabolism and interleukin-8 production in human human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae. J Antimicrob Chemother. 2000;46:19-26.
15. Anderson R, Tintinger G, Cockeran R, et al. Beneficial and harmful interactions of antibiotics with microbial pathogens and the host innate immune system. Pharmaceuticals. 2010;3(5):1694-1710.
16. Bhatt V, Saleem A., Drug-induced neutropenia: pathophysiology, clinical features, and management. Ann Clin Lab Sci. 2004;34(2):131-137.
17. Neftel KA, Simon PH, Müller MR. Inhibition of granulopoiesis in vivo and in vitro by beta-lactam antibiotics. J Infec Dis. 1985;152(1):90-98.
18. Scheetz MH, McKoy J, Parada J, et al. Systematic review of piperacillin-induced neutropenia. Drug Safety. 2007;30(4):295-306.
19. Hsiao S-H, Chang C, Tsai J, et al. Glycopeptide-induced neutropenia: cross-reactivity between vancomycin and teicoplanin. Ann Pharmacother. 2007;41(5):891-894.
20. Pai MP, Mercier RC, Koster SA. Epidemiology of vancomycin-induced neutropenia in patients receiving home intravenous infusion therapy. Ann Pharmacother. 2006;40(2):224-228.
21. Culic O, Erakovic V, Cepelak I, et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol. 2002;50(3):277-289.
22. Sharma S, Jaffe A, Dixon G. Immunomodulatory effects of macrolide antibiotics in respiratory disease: therapeutic implications for asthma and cystic fibrosis. Paediatr Drugs. 2007;9(2):107-118.
23. Tauber SC. Immunomodulatory properties of antibiotics. Curr Molecul Pharmacol. 2008;1(1):68-79.
24. Koch CC, Estaban D, Chin A, et al. Apoptosis, oxidative metabolism and interleukin-8 production in human human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae. J Antimicrob Chemother. 2000;46:19-26.
25. Aoshiba K, Nagai A, Konno K. Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob Agents Chemother. 1995;39(4):872-877.
26. Shalit I, et al. Immunomodulatory and protective effects of moxifloxacin against Candida albicans-induced bronchopneumonia in mice injected with cyclophosphamide. Antimicrob Agents Chemother. 2002;46:2442-2449.
27. Shalit I, Kletter Y, Weiss K, et al. Enhanced hematopoiesis in sublethally irradiated mice treated with various quinolones. Eur J Haematol. 1997;58:92-98.
28. Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis. 2003;3:359-371.
29. Shalit I, et al. Immunomodulatory effects of moxifloxacin in comparison to ciprofloxacin and G-CSF in a murine model of cyclophosphamide-induced leukopenia. Eur J Haematol. 2001:;66: 287-296.
30. Ariza A, Montañez MI, Pérez-Sala D. Proteomics in immunological reactions to drugs. Curr Opin Aller Clinic Immunol. 2011;11(4):305-312.
31. Martin SF. T lymphocyte-mediated immune responses to chemical haptens and metal ions: implications for allergic and autoimmune disease. Int Arch Aller Immunol. 2004;134(3):186-198.
32. Weitzman S, Stossel T. Drug-induced immunological neutropenia. Lancet. 1978;311(8073):1068-1072.
33. Carey PJ. Drug-induced myelosuppression diagnosis and management. Drug Safety. 2003;26:691-706.
34. Bjornson BH, McIntyre A, Harvey J, Tauber A. et al. Studies of the effects of trimethoprim and sulfamethoxazole on human granulopoiesis. Am J Hematol. 1986;23:1-7.
35. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 2002;109:625-637.
36. Tjwa M, et al. Antibiotics may impair hematopoietic recovery after cytotoxic myeloablation. Blood.2009;113:1608-1609.
37. Apinantriyo, B., A. Lekhakula, and P. Rujirojindakul. Incidence, etiology and bone marrow characteristics of non-chemotherapy-induced agranulocytosis. Hematology. 2011; 16:50-53.
38. Van der Klauw, M.M., J.H.P. Wilson, and B.H.Ch. Stricker. Drug-induced agranulocytosis: 20 years of reporting in the Netherlands (1974-1994). American Journal of Hematology. 1998; 57:206-211.
39. Montserrat M, et al. Venlafaxin and/or clindamycin induced agranulocytosis: a case report. International Journal of Clinical Pharmacy. 2011; 33:290.
40. Pisciotta AV. Agranulocytosis during antibiotic therapy: drug sensitivity or sepsis? American Journal of Hematology. 1993; 42:132-137.
41. Khan, A.Y., M.H. Golewale, D.A. Kahn. A case of chronic drug-induced neutropenia. Journal of Psychiatric Practice. 2008; 14: 246-250.
42. Healy, D.P., et al., Effect of Antibiotics on Polymorphonuclear Neutrophil Apoptosis. Pharmacotherapy, 2002. 22(5): p. 578-585.
43. Shuman MD, Trigoboff E, Demler TL. Adverse Drug Reactions Involving Clozapine Recipients. Presented at ASHP Midyear Clinical Meeting; December 7, 2011; New Orleans, LA.